Project description DEENESFRITPL Antibody therapy against COVID-19 Passive immunotherapy, through the transfer of antibodies, has been proposed as a potential approach for treating patients with COVID-19. Building on previous experience of antibody therapy against SARS- and MERS-CoV, scientists of the EU-funded ATAC project will characterise human antibodies obtained from the blood of recovered coronavirus patients from China and Italy. Using a combination of experimental and computational work, they will optimise, produce and test all antibodies before selecting the most effective candidate for therapy. The rapid dissemination of the project's results will help the medical community respond to the current COVID-19 pandemic through improved patient management. Show the project objective Hide the project objective Objective ATAC aims at developing passive immunotherapy against COVID-19. Human antibodies will be obtained from blood of CoV-recovered donors from China and Italy with three independent approaches: polyclonal gamma-globulins, B cell monoclonals and phage libraries. Antibodies will be characterized by rapid experimental and computational work, optimized, produced and tested in consultation with EMA to ensure prompt embedding of regulatory aspects. The partners have outstanding experience in all aspects of the project, collaborated previously and worked on antibody therapy for diseases including SARS and MERS-CoV. Reagents and experienced personnel are already available ensuring quick and efficient progress, with initial deliverables within 3 months.Besides providing a lead human antibody candidate for therapy, ATAC will rapidly disseminate results to help respond to the current COVID-19 epidemic. Results of the 40 months project will also further our understanding of CoV neutralization, contributing to future vaccination and therapeutic strategies.The team includes the Karolinska Institutet (SE, Pan-Hammarström and Hammarström, coordinators), the Institute for Research in Biomedicine (CH, Varani and Robbiani); the Joint Research Centre- European Commission (BE, Calzolai); Technische Universität Braunschweig (DE, Hust) and Policlinico San Matteo (IT, Baldanti). The partners’ outstanding expertise is attested by high impact publications on antibody treatment for emerging infectious diseases. Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses Keywords Coronavirus passive immunisation polyclonal antibodies monoclonal antibodies recombinant antibodies Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-PHE-CORONAVIRUS-2020 - Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic Call for proposal H2020-SC1-PHE-CORONAVIRUS-2020 See other projects for this call Funding Scheme RIA - Research and Innovation action Coordinator KAROLINSKA INSTITUTET Net EU contribution € 849 143,00 Address Nobels Vag 5 17177 Stockholm Sweden See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 855 396,25 Participants (4) Sort alphabetically Sort by Net EU contribution Expand all Collapse all FONDAZIONE PER L'ISTITUTO DI RICERCA IN BIOMEDICINA Switzerland Net EU contribution € 3 923 145,00 Address VIA FRANCESCO CHIESA 5 6500 Bellinzona See on map Region Schweiz/Suisse/Svizzera Ticino Ticino Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 935 025,00 JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION Belgium Net EU contribution € 221 695,00 Address Rue de la Loi 200 1049 Bruxelles / Brussel See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 223 545,00 TECHNISCHE UNIVERSITAET BRAUNSCHWEIG Germany Net EU contribution € 265 111,00 Address UNIVERSITAETSPLATZ 2 38106 Braunschweig See on map Region Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 267 323,75 FONDAZIONE IRCCS POLICLINICO SAN MATTEO Italy Net EU contribution € 335 946,00 Address VIALE GOLGI 19 27100 Pavia See on map Region Nord-Ovest Lombardia Pavia Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 338 750,00
